← Back to Blog

Impact of Substance Schedule Classification on Anesthesia Research

The Controlled Substances Act (CSA) establishes five schedules for drug control based on a substance’s medical utility, safety profile, and potential for abuse.¹ Anesthesia research and clinical practice are intrinsically linked to these classifications, as the field relies heavily on controlled central nervous system (CNS) agents to induce unconsciousness and manage severe pain.² However, the schedule classification of these drugs creates a complex balance between preventing substance abuse risk and advancing medical science, which significantly influences anesthesia research.

The most formidable barrier in anesthesia and pain research involves Schedule I drugs, which are federally defined as having a high potential for abuse and lacking a currently accepted medical use.^1,3 This strict classification creates a regulatory “Catch-22” for researchers: a drug cannot be legally accepted for medical use without rigorous clinical trials, yet conducting this research is severely obstructed because the drug is on Schedule I.³ For example, diamorphine (heroin) is strictly prohibited in the United States, keeping its clinical research virtually non-existent.³ In stark contrast, the United Kingdom has a history of routinely prescribing diamorphine as an effective analgesic for labor pain, pediatric acute pain, and pulmonary edema.³ Stringent regulations, fear of legal consequences, and the social stigma associated with substances in the Schedule I classification block research into any therapeutic potential for pain management or anesthesia.³

Drugs with accepted medical uses but high abuse potentials are placed in less restrictive categories, though they still face substantial oversight.¹ As a Schedule II opioid agonist, fentanyl remains a cornerstone medication used for induction, maintenance, and postoperative recovery in general and regional anesthesia.³ Because of its high risk for addiction, abuse, and life-threatening respiratory depression, clinical research and administration require highly specialized environments equipped with opioid antagonists and resuscitative equipment.²

Ketamine, a dissociative anesthetic and NMDA receptor antagonist, is classified as Schedule III.^1,4 This comparatively less restrictive classification reflects its medically accepted use and lower risk abuse profile. This flexibility has facilitated broader research into novel off-label applications, such as intramuscular or sublingual administration for treatment-resistant psychiatric disorders.⁴

When researchers develop novel anesthetics or analgesics, the U.S. Food and Drug Administration (FDA) requires rigorous abuse potential assessments. These directly inform the “Eight-Factor Analysis,” a formal scientific and medical evaluation used for determining whether a drug should be controlled under the CSA, and if so, into which of the five schedules it should be placed.^1,5 These assessments are critical because overly restrictive scheduling can strongly disincentivize the pharmaceutical industry from developing novel medications.⁵ Pharmaceutical sponsors often target the lowest possible schedule to ensure accessibility. However, unpredictable evaluations may push novel drugs into more restrictive categories, potentially stifling innovation in anesthesia pharmacology.⁵

Anesthesia research involving controlled substances also faces intense ethical scrutiny. Institutional Review Boards (IRBs) and funding agencies often exhibit skepticism or fear reputational damage when evaluating research on controversial drugs for therapeutic benefits.³ For instance, federal agencies like the National Institute on Drug Abuse (NIDA) have historically prioritized researching drug harms and abuse reduction over potential medicinal benefits.³ Furthermore, ethical complications frequently arise regarding informed consent, the risk of undue inducement when offering controlled substances in clinical trials, and the complex risk-benefit calculus required to safely protect research subjects.³

Ultimately, the schedule classification of substances under the CSA is essential for protecting the public from drug abuse, but it undeniably restricts the scope and pace of anesthesia research.⁵ To advance pain management and anesthetic care, regulatory frameworks must find a careful balance between harm reduction and scientific advancement while prioritizing evidence-based, impartial evaluations.

References

1. Calderon SN, Bonson KR, Reissig CJ, Lloyd JM, Galati S, Chiapperino D. Considerations in assessing the abuse potential of psychedelics during drug development. Neuropharmacology. 2023 Feb 15;224:109352. doi: 10.1016/j.neuropharm.2022.109352. Epub 2022 Nov 28. PMID: 36455646.

2. Fentanyl Citrate Injection [package insert]. Silver Spring (MD): US Food and Drug Administration; 2023 Dec [cited 2026 Jun 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/019115s042lbl.pdf

3. Andreae MH, Rhodes E, Bourgoise T, Carter GM, White RS, Indyk D, Sacks H, Rhodes R. An Ethical Exploration of Barriers to Research on Controlled Drugs. Am J Bioeth. 2016;16(4):36-47. doi: 10.1080/15265161.2016.1145282. PMID: 26982922; PMCID: PMC4849133.

4. Reiff CM, Richman EE, Nemeroff CB, Carpenter LL, Widge AS, Rodriguez CI, Kalin NH, McDonald WM; the Work Group on Biomarkers and Novel Treatments, a Division of the American Psychiatric Association Council of Research. Psychedelics and Psychedelic-Assisted Psychotherapy. Am J Psychiatry. 2020 May 1;177(5):391-410. doi: 10.1176/appi.ajp.2019.19010035. Epub 2020 Feb 26. PMID: 32098487.

5. Henningfield JE, Comer SD, Banks ML, Coe MA, Collins GT, Cooper ZD, Fantegrossi WE, Durgin CJ, Heal DJ, Huskinson SL, Lanier RK, Lynch WJ, Meisch RA, Rowlett JK, Strickland JC, Gannon BM. Abuse potential assessment of novel central nervous system active and psychedelic substances for controlled substances act scheduling recommendations. J Psychopharmacol. 2026 Jan;40(1):212-223. doi: 10.1177/02698811251378511. Epub 2025 Nov 3. PMID: 41185108; PMCID: PMC13198618.